---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-189463"
form_type: "8-K"
ticker: "ALEC"
cik: "0001653087"
company_name: "Alector, Inc."
filed_at: "2022-07-07T23:59:59+00:00"
generated_at: "2026-06-24T19:41:01.669161+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# AbbVie terminates Alector's AL003/CD33 Alzheimer's collaboration

## Summary
- AbbVie provided written notice on June 30, 2022 terminating the CD33 (AL003) program.
- Alector and AbbVie continue to advance the AL002 (TREM2) program under the existing agreement.
- No financial or milestone termination payments disclosed in the filing.

## SEC filing metadata
- accession: 0001193125-22-189463
- form_type: 8-K
- ticker: ALEC
- cik: 0001653087
- company_name: Alector, Inc.
- filed_at: 2022-07-07T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1653087/000119312522189463/0001193125-22-189463-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1653087/000119312522189463/d317537d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-189463
- JSON: https://secwatch.observer/filing/0001193125-22-189463.json
- Plain text: https://secwatch.observer/filing/0001193125-22-189463.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.